Long-term outcome of imatinib 400 m g compared to imatinib 600 m g or imatinib 400 m g daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
Guilhot,F., Rigal-Huguet,F., Guilhot,J., Guerci-Bresler,A.P., Maloisel,F., Rea,D., Coiteux,V., Gardembas,M., Berthou,C., Vekhoff,A., Jourdan,E., Berger,M., Fouillard,L., Alexis,M., Legros,L., Rousselot,P., Delmer,A., Lenain,P., Escoffre Barbe,M., Gyan,E., Bulabois,C.E., Dubruille,V., Joly,B., Pollet,B., Cony-Makhoul,P., Johnson-Ansah,H., Mercier,M., Caillot,D., Charbonnier,A., Kiladjian,J.J., Chapiro,J., Penot,A., Dorvaux,V., Vaida,I., Santagostino,A., Roy,L., Zerazhi,H., Deconinck,E., Maisonneuve,H., Plantier,I., Lebon,D., Arkam,Y., Cambier,N., Ghomari,K., Miclea,J.M., Glaisner,S., Cayuela,J.M., Chomel,J.C., Muller,M., Lhermitte,L., Delord,M., Preudhomme,C., Etienne,G., Mahon,F.X., Nicolini,F.E., france Intergroupe des Leucemies Myeloides,Fi-LMC
Revue : Leukemia -
2021 /
1
Volume : 35
Pages : 2332-2345